Zenas BioPharma to Host Virtual R&D Event
Key Highlights
- ➤Zenas will host a virtual R&D event on October 27, 2026.
- ➤Obexelimab is being evaluated in systemic lupus erythematosus.
- ➤ZB021 development centers on an oral IL-17AA/AF inhibitor.
- ➤Zenas is advancing late-stage obexelimab and orelabrutinib programs.
Expert Statements
Joseph F. Merola, Dermatologist, Rheumatologist, President of the Rheumatologic Dermatology Society, Medical and Scientific Board of the Lupus Foundation of America
“will provide key insights into the biology and clinical considerations”
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host a virtual R&D event on Tuesday, October 27, 2026, from 8:00 – 9:30 a.m. ET.
The event will include presentations from Zenas’ management team on the overall R&D pipeline including obexelimab, our investigational bifunctional monoclonal antibody targeting CD19 and FcyRIIb, currently being evaluated in systemic lupus erythematosus, as well as the ongoing development of ZB021, Zenas’ oral IL-17AA/AF inhibitor. Dr. Joseph F. Merola, MD, MMSc, Dermatologist, Rheumatologist, President of the Rheumatologic Dermatology Society, Medical and Scientific Board of the Lupus Foundation of America, will provide key insights into the biology and clinical considerations.
Get started
Create a free account to read the full story.